|
Medarex Appoints W. Bradford Middlekauff as Vice President, General Counsel and Secretary PRINCETON, N.J., May 25, 2000 /PRNewswire via COMTEX/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that W. Bradford Middlekauff has been named Vice President, General Counsel and Secretary. This is a newly created position in which Mr. Middlekauff will be responsible for all legal matters affecting the company and will oversee Medarex`s legal department. Mr. Middlekauff has served in both business and legal capacities in the biopharmaceutical industry. Prior to joining Medarex, he was Vice President, Business Development and General Counsel at Algos Pharmaceutical Corporation. He came to Algos Pharmaceutical from Cooley Godward, in Palo Alto, California, where he advised life science companies on the business and legal aspects of corporate partnering, licensing, intellectual property, research and development, manufacturing, product commercialization, corporate financings and SEC compliance. "Brad`s solid legal experience is key to Medarex. He brings to us vast knowledge in the biopharmaceutical and business development fields -- two areas that are essential to the advancement of our business," said Donald L. Drakeman, President and CEO of Medarex. "Through the addition of Brad, we continue to strengthen our management team." Mr. Middlekauff received a J.D. degree from Yale Law School and an A.B. degree from Brown University. Medarex is a biopharmaceutical company developing monoclonal antibody- based therapeutics to fight cancer and other life-threatening and debilitating diseases. The Company has developed a broad platform of patented technologies for antibody discovery and development, including the HuMAb-Mouse(TM) system for the creation of high-affinity human antibodies. Medarex`s HuMAb-Mouse technology is a transgenic mouse system that creates high affinity, fully human antibodies instead of mouse antibodies. Using standard, well proven laboratory techniques, scientists can produce these fully human antibodies in a matter of months. Medarex creates and develops human antibodies for itself and others, offering a full range of antibody development capabilities, including pre-clinical and clinical manufacturing services. For more information about the company visit its web site at www.medarex.com. Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of the company`s product candidates, uncertainties related to business opportunities, the receipt of future payments, the continuation of business partnerships and other risks detailed from time to time in the company`s filings with the Securities and Exchange Commission (SEC). |
|
| aus der Diskussion: | Medarex----wer jetzt nich nachkauft ist selber schuld!!!!! |
| Autor (Datum des Eintrages): | volkswagen (25.05.00 20:45:50) |
| Beitrag: | 10 von 47 (ID:989529) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |